NovaBay Pharmaceuticals Inc
$ 0.76
1.10%
06 Feb - close price
- Market Cap 95,905,000 USD
- Current Price $ 0.76
- High / Low $ 0.94 / 0.76
- Stock P/E 0.15
- Book Value -0.45
- EPS 5.16
- Next Earning Report 2026-04-01
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.87 %
- ROE -5.16 %
- 52 Week High 19.95
- 52 Week Low 0.30
About
NovaBay Pharmaceuticals Inc. (NBY), based in California, is a forward-looking biotechnology company focused on transforming ocular health through cutting-edge medical devices and therapeutics designed to combat eye infections and inflammation. Leveraging its proprietary technologies, NovaBay is poised to address substantial unmet clinical needs in the rapidly growing eye care market. As the company advances its innovative product pipeline and seeks to bring new therapies to market, it represents a promising investment opportunity for institutional investors aiming to capitalize on healthcare advancements that enhance patient outcomes.
Analyst Target Price
$0.85
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-07 | 2025-08-12 | 2025-04-02 | 2024-12-31 | 2024-11-07 | 2024-08-13 | 2024-05-09 | 2024-03-26 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-30 |
| Reported EPS | -0.23 | -0.34 | -0.4 | -0.3988 | -0.59 | -1.37 | -0.15 | -1.33 | -0.37 | -0.64 | -0.85 | -0.78 |
| Estimated EPS | -0.01 | -0.21 | -0.24 | -0.24 | -0.3 | -1.23 | -0.15 | -0.3 | -0.4 | -0.56 | -0.91 | -0.17 |
| Surprise | -0.22 | -0.13 | -0.16 | -0.1588 | -0.29 | -0.14 | 0 | -1.03 | 0.03 | -0.08 | 0.06 | -0.61 |
| Surprise Percentage | -2200% | -61.9048% | -66.6667% | -66.1667% | -96.6667% | -11.3821% | 0% | -343.3333% | 7.5% | -14.2857% | 6.5934% | -358.8235% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-04-01 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Previous Dividend Records
| Sep 2025 | |
|---|---|
| Payment Date | 2025-09-29 |
| Amount | $0.8 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NBY
2026-01-31 05:30:27
NovaBay Pharmaceuticals has scheduled a special shareholder meeting for March 12, 2026, to vote on proposals to issue common stock, which will result from the exercise of pre-funded warrants issued in private placements in October 2025 and January 2026. Spark, TipRanks' AI Analyst, rates NBY as Neutral due to weak financial performance and dilution risks despite improving capital access. The stock currently has a Sell rating from analysts with a $3.00 price target.
2026-01-31 01:29:46
NovaBay Pharmaceuticals announced the appointment of CBIZ CPAs, P.C. as its new independent registered public accounting firm for the fiscal year ending December 31, 2025. The company will also hold a special shareholder meeting on March 12, 2026, to vote on proposals including the issuance of common stock related to pre-funded warrants. These announcements follow recent financial maneuvers by NovaBay, including an ATM sales agreement and a private placement of pre-funded warrants, aimed at raising capital and bolstering its financial position.
2026-01-28 21:27:56
NovaBay Pharmaceuticals, Inc. (NBY) announced that its longtime auditor, WithumSmith+Brown, PC, will not seek reappointment for the fiscal year 2025. This change comes as NovaBay seeks stockholder approval to dissolve and distribute its remaining assets. The company clarified that there were no disagreements or reportable events with Withum, and the audit reports for 2023 and 2024 were clean, except for an explanatory paragraph about the dissolution plan.
2026-01-21 20:28:40
NovaBay Pharmaceuticals (NBY) saw its stock price drop by 14.3% on Wednesday, trading at $5.568 with significantly lower than average volume. The company, which specializes in non-antibiotic anti-infectives and has a market capitalization of $731.49 million, has attracted some institutional investor attention. Despite the dip, analysts currently rate NBY as a "Hold," suggesting other stocks might be better buys according to top-rated analysts.
2026-01-21 07:27:36
NovaBay Pharmaceuticals (NYSE:NBY) has announced a new at-the-market (ATM) sales agreement with Virtu Americas LLC, allowing it to offer and sell up to $100 million worth of its common stock. This agreement provides NovaBay with flexibility in financing through direct market sales, with Virtu acting as the sales agent. This follows a recent private placement deal involving pre-funded warrants, indicating active financial maneuvers by the company.
2026-01-20 18:58:02
NovaBay Pharmaceuticals (NBY) saw a significant drop in its stock price after announcing an at-the-market sales agreement with Virtu Americas. The agreement allows NovaBay to sell up to $100M worth of its common stock. This news led to a ~54% decrease in the company's valuation.
